Dhruv KhullarOvjeren akaunt

@DhruvKhullar

doctor | researcher | writer |

New York, NY
dhruvkhullar.com
Vrijeme pridruživanja: lipanj 2009.
116 fotografija ili videozapisa Fotografije i videozapisi

Tweetovi

Blokirali ste korisnika/cu @DhruvKhullar

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @DhruvKhullar

  1. Prikvačeni tweet
    30. sij

    Excited to share new work : Drug prices are a major concern for Americans. We describe the many levers policymakers have—beyond price negotiation—to reduce the cost burden on patients, while maintaining incentives for the innovation society needs.

    24 proslijeđena tweeta 84 korisnika označavaju da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  2. proslijedio/la je Tweet
    4. velj

    With funding from , we found health systems publicly announced $2.5B in investments in social determinants in just last 2 years: largest going to housing at $1.6B and employment $1.1B

    1 reply 11 proslijeđenih tweetova 40 korisnika označava da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  3. proslijedio/la je Tweet
    30. sij

    In a national drug pricing debate begging for nuance, this work and data visualization is 🔥🔥🔥

    Excited to share new work : Drug prices are a major concern for Americans. We describe the many levers policymakers have—beyond price negotiation—to reduce the cost burden on patients, while maintaining incentives for the innovation society needs.
    Prikaži ovu nit
    1 reply 1 proslijeđeni tweet 6 korisnika označava da im se sviđa
    Poništi
  4. 30. sij

    Reminded of the beauty of 's writing when re-reading this on diagnostic uncertainty: "Possibility is not the same as probability, but when you’re bearing the weight of another person’s life, the distinction often feels meaningless."

    2 proslijeđena tweeta 25 korisnika označava da im se sviđa
    Poništi
  5. 30. sij

    Disheartening findings in new report: US spends much more on health care than other developed countries, but has the lowest life expectancy, highest suicide rates, and highest rates of avoidable deaths.

    1 reply 6 proslijeđenih tweetova 7 korisnika označava da im se sviđa
    Poništi
  6. 30. sij

    The central insight is that America's drug market is anything but a traditional free market. Lawmakers have constructed every aspect of the system—and thus have many options, beyond price negotiation, to change the calculus for drug innovation & the costs to patients.

    1 proslijeđeni tweet 4 korisnika označavaju da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  7. 30. sij

    Finally, the Competitive Period starts when other companies are allowed to introduce products to compete with the innovator drug. Again, policymakers determine when & how generics can compete—which profoundly influences drug company profits, as patents & exclusivities expire.

    1 reply 2 korisnika označavaju da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  8. 30. sij

    If/when a drug is approved, the Monopoly Period begins. This is where the majority of the reward for successful innovation is earned. Policymakers can influence incentives by deciding how long and how thoroughly new drugs should be protected from competition.

    1 reply 2 korisnika označavaju da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  9. 30. sij

    In the Innovation Period, drugs are developed & tested. Process is risky but there are many ways to reduce risk & cost without allowing companies to charge exorbitant prices. Question for policymakers is: What is allowed into the market and how much should it cost to get there?

    1 reply 2 korisnika označavaju da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  10. 30. sij

    We explore the 3 stage journey every drug makes during its life—and how adjusting the rewards & costs for drugmakers during each period can influence the overall reward for innovation. (The Interactive Graphic lets readers see how each policy influences this reward system.)

    1 reply 5 korisnika označava da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  11. proslijedio/la je Tweet
    29. sij

    Just out from et al. The structure of rewards (and costs) in pharmaceutical drug development. We introduce the 'reward box' interactive graphic to see how the elements interplay, how specific policies affect it.

    31 proslijeđeni tweet 55 korisnika označava da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  12. 28. sij

    Excited to see this collaboration between & !

    Today is excited to announce our work with to enable a value-based payment model for mental health care. Together, we will improve the quality of mental health care that patients receive.
    2 proslijeđena tweeta 4 korisnika označavaju da im se sviđa
    Poništi
  13. proslijedio/la je Tweet
    23. sij

    Treating Regret Excellent article by on the consequences of neglecting regret on everyone and calls on health care providers to recognize the impact of regret on patients and families. /1

    5 proslijeđenih tweetova 6 korisnika označava da im se sviđa
    Poništi
  14. proslijedio/la je Tweet
    23. sij

    Regrets, I've had a few: Despite the pervasiveness of regret, doctors often overlook it, by via

    2 proslijeđena tweeta 6 korisnika označava da im se sviđa
    Poništi
  15. 22. sij

    Regret is a powerful emotion many patients & clinicians experience, but one that often goes unexplored. In , I discuss how we can work through regret—and focus not on what might have been but on what still is.

    1 reply 5 proslijeđenih tweetova 21 korisnik označava da mu se sviđa
    Poništi
  16. proslijedio/la je Tweet
    21. sij

    New descriptive paper with and Zeke Emanuel in examining association between county-level social mobility (a measure of economic opportunity) and life expectancy at age 40: 1/

    42 proslijeđena tweeta 86 korisnika označava da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  17. proslijedio/la je Tweet
    13. sij

    Our new paper (w/ + ): patterns of turnover in the physician workforce likely contribute to provider consolidation. (1/7)

    28 proslijeđenih tweetova 67 korisnika označava da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  18. 13. sij

    Thanks to the entire team who worked so hard to make this seamless video visit service available to patients. If you, a friend, or a family member want to learn more about treatment options available, please check it out or spread the word.

    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  19. 13. sij

    Excited to announce a new product : our cancer video concierge service. In a few clicks, newly-diagnosed breast cancer patients can schedule a free, personalized video visit with our fantastic RNs & learn about onc care available

    2 proslijeđena tweeta 22 korisnika označavaju da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  20. 8. sij

    Today my computer broke, so I had to write by hand and it was the most productive day I've had in months, but now my computer is working again, so I'm sending this tweet.

    6 replies 4 proslijeđena tweeta 136 korisnika označava da im se sviđa
    Poništi

@DhruvKhullar još nije objavio nijedan Tweet.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·